Kiora Pharmaceuticals, Inc. (KPRX) — Financial statements
Income statement, balance sheet, and cash flow for Kiora Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 16 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -0.02↓100.2% | 16 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 11↑120.1% | 5↑21.6% | 4↑16.8% | 3↓35.5% | 5 | |
| General & Administrative Expenses | 6↑3.7% | 6↑18.9% | 5↓43.7% | 8↑55.5% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 6↑3.7% | 6↑18.9% | 5↓43.7% | 8↑55.5% | 5 | |
| Other Expenses | -7↓775.0% | 1↓73.0% | 4↑568.8% | 0.58↓83.6% | 4 | |
| Operating Expenses | 9↓17.9% | 11↓8.7% | 13↑2.3% | 12↓13.5% | 14 | |
| Total Costs & Expenses | 9↓17.7% | 11↓8.7% | 13↑2.3% | 12↓13.5% | 14 | |
| Operating Results | ||||||
| Operating Income | -9↓309.7% | 5↑135.8% | -13↓2.3% | -12↑13.5% | -14 | |
| Depreciation & Amortization | 0.02↑29.1% | 0.02↓62.9% | 0.05↑24.5% | 0.04↓8.1% | 0.05 | |
| EBITDA | -9↓265.5% | 6↑146.1% | -12↑9.4% | -14↑1.9% | -14 | |
| EBIT | -9↓266.5% | 6↑145.8% | -12↑9.3% | -14↑1.9% | -14 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.87↓29.0% | 1↑656.1% | 0.16↑237.2% | 0.05↑945.7% | -0.01 | |
| Interest Income | 0.89↓28.6% | 1↑620.1% | 0.17↑205.8% | 0.06↑4886.1% | 0.00 | |
| Interest Expense | 0.02↓6.9% | 0.02↑92.7% | 0.01↑29.5% | 0.01↑25.5% | 0.01 | |
| Non-Operating Income | 0.00↑100.0% | -1↓571.2% | -0.17↓112.7% | 1↑593.5% | -0.28 | |
| Other Income / Expenses | -3↓331.2% | 1↑603.8% | 0.16↑111.8% | -1↓609.1% | 0.27 | |
| Income Before Tax | -12↓314.1% | 6↑145.6% | -12↑9.3% | -14↑1.9% | -14 | |
| Income Tax Expense | -1↓162.1% | 2↑2186.3% | 0.09↑179.9% | -0.11↑41.3% | -0.19 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -11↓401.4% | 4↑128.7% | -13↑7.9% | -14↑1.4% | -14 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -11↓401.4% | 4↑128.7% | -13↑7.9% | -14↑1.4% | -14 | |
| Bottom-Line Net Income | -11↓401.4% | 4↑127.6% | -13↑4.0% | -14↑1.4% | -14 | |
| EPS (Basic) | -2.60↓379.6% | 0.93↑103.8% | -24.25↓30.7% | -18.55↑72.7% | -68.00 | |
| EPS (Diluted) | -2.64↓403.4% | 0.87↑103.6% | -24.25↓30.7% | -18.55↑72.7% | -68.00 | |
| Weighted Average Shares | 4↑7.6% | 4↑619.8% | 0.54↓26.5% | 0.73↑203.7% | 0.24 | |
| Weighted Average Diluted Shares | 4↓0.5% | 4↑666.7% | 0.54↓26.5% | 0.73↑203.7% | 0.24 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.